企業概要
Koninklijke Philips N.V. operates as a health technology enterprise providing diagnostic imaging solutions, ultrasound business units, and connected care technologies across North America, Greater China, and international markets. The company functions within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a focus on high-precision engineering and regulatory compliance essential for patient care. Philips manages a substantial workforce comprising 61,085 employees and maintains a market capitalization of $25.67 billion alongside an annual revenue of $17.83 billion. These valuation and revenue figures indicate that the company holds a significant position within the global medical device landscape, serving as a major entity in the diagnosis and treatment ecosystem.
財務健全性
The company reported total revenue of $17.83 billion over the trailing twelve months, generating a net income of $899.00 million and an EBITDA of $2.02 billion. The substantial gap between the $17.83 billion in revenue and the $899.00 million in net income reveals a cost structure where operating expenses and taxes consume approximately 95% of total top-line revenue before reaching the bottom line. Free cash flow stands at $453.00 million, indicating that after capital expenditures, the company retains sufficient liquidity to fund operations, pay dividends, or invest in R&D without external financing. Gross margin is recorded at 45.2%, reflecting strong pricing power or cost efficiencies in manufacturing medical devices, while the operating margin of 10.7% suggests healthy operational control over direct and indirect costs. The profit margin of 5.0% demonstrates the final percentage of revenue converted into earnings, highlighting the competitive pressures or high fixed costs inherent in the industry. On the balance sheet, cash assets total $2.79 billion against a debt load of $8.09 billion, resulting in a debt-to-equity ratio of 73.57%, which suggests a leveraged capital structure rather than a conservative one. The current ratio of 1.32 indicates that current assets exceed current liabilities by a modest margin, signaling adequate but not excessive short-term liquidity to cover immediate obligations. Return on equity is 7.8% and return on assets is 3.2%, metrics that reveal the efficiency with which management utilizes shareholder capital and total assets to generate profits, with ROE notably higher due to the leverage effect.
バリュエーション評価
The trailing twelve-month P/E ratio is 25.03, while the forward P/E is projected at 12.84. This significant disparity between the trailing and forward multiples implies that the market expects earnings to grow substantially in the future, compressing the current valuation multiple as anticipated profitability increases. The price-to-book ratio stands at 2.01, indicating that the market values the company at twice its net asset value, suggesting a premium assigned to intangible assets like brand equity, patents, and technology rather than just physical book value. Alternative valuation metrics include a price-to-sales ratio of 1.44 and an EV/EBITDA of 15.28, which provide context for valuation relative to revenue generation and enterprise cash flow generation, respectively. Regarding trading range, the 52-week high is $33.44 and the 52-week low is $21.48. Without the current share price explicitly listed in the provided facts, the relative position within the range cannot be calculated numerically, though the beta of 0.94 indicates that the stock's price volatility is slightly lower than the broader market, moving in tandem with general market fluctuations.
Growth & Income
Revenue growth year-over-year is recorded at 1.1%, while earnings growth year-over-year is listed as N/A. The absence of reported earnings growth data prevents a direct comparison of earnings expansion versus revenue expansion, leaving the trajectory of profitability growth undefined based solely on the available metrics. As a dividend payer, Philips offers a dividend yield of 3.8% with a payout ratio of 91.7%. A payout ratio exceeding 90% is high and suggests that the company distributes the vast majority of its earnings to shareholders, which may limit internal reinvestment capacity for growth initiatives compared to companies with lower payout ratios. The sustainability of this dividend depends on maintaining or improving profit margins and controlling operating expenses, as any decline in net income could pressure the ability to sustain such a high payout level without cutting the dividend. The overall growth and income profile presents a scenario of stable but slow revenue expansion supported by a high-yield dividend, characteristic of mature healthcare infrastructure companies.